CH5:LSE:LSE-Amundi ETF MSCI Europe Healthcare UCITS ETF (GBX)

ETF | Others |

Last Closing

USD 34355

Change

+75.00 (+0.22)%

Market Cap

USD 0.06B

Volume

15.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R15:LSE SoftBank Group Corp.

+180.00 (+2.15%)

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

+280.00 (+3.37%)

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

-1.50 (-0.80%)

USD 1,607.29B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.04 (-0.27%)

USD 642.91B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.04 (-0.24%)

USD 636.40B
0R1I:LSE NVIDIA Corp.

+5.05 (+0.54%)

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

+5.75 (+0.28%)

USD 320.04B
0QZK:LSE Coca-Cola Co.

+0.40 (+0.63%)

USD 266.08B
0QZO:LSE 0QZO

+1.30 (+1.27%)

USD 258.54B

ETFs Containing CH5:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.23% 84% B 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.23% 83% B 75% C
Trailing 12 Months  
Capital Gain 3.85% 39% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.85% 37% F 48% F
Trailing 5 Years  
Capital Gain 63.99% 82% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.99% 80% B- 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 8.23% 66% D+ 69% C-
Dividend Return 8.23% 65% D 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 6.88% 79% B- 89% A-
Risk Adjusted Return 119.68% 99% N/A 100% F
Market Capitalization 0.06B 38% F 34% F

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.